The Sweet-Water Trial - A Multicenter, Pragmatic, Embedded Open-Label, Stepped-Wedge, Cluster-Randomized Trial comparing glucose 5% with sodium chloride 0.9% as the default drug diluent in the ICU

The Sweet-Water Trial - A Multicenter, Pragmatic, Embedded Open-Label, Stepped-Wedge, Cluster-Randomized Trial comparing glucose 5% with sodium chloride 0.9% as the default drug diluent in the ICU - Sweet-Water Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033397

Enrollment

4440

Registered

2024-06-24

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E87.0

Interventions

Group 1: NaCl 0.9% is used as the default drug solvent for all compatible intravenous medications, according to a drug solvation and dilution standard table. Group 2: Glucose 5% is used as the default

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: None

Exclusion criteria

Exclusion criteria: Admission for acute brain injury (traumatic brain injury, aneurysmal subarachnoid hemorrhage, or intracerebral hemorrhage) Hyponatremia (sodium levels below 130 mmol/L) at ICU admission.

Design outcomes

Primary

Measure	Time frame
ICU-acquired hypernatremia >150 mmol/l through day 28 Number of days alive and free of the ICU through day 28 (=ICU-free days through day 28)	—

Secondary

Measure	Time frame
1. ICU mortality 2. Hospital-free days through day 28 3. In-Hospital Mortality 4. Length of Stay in the ICU 5. Length of Stay in the hospital 6. Ventilator free days through day 28 7. Prevalence of new kidney replacement therapy in the first 28 days 8. Duration of new kidney replacement therapy in the first 28 days 9. Peak Creatinine in the first 28 days 10. Sodium concentration on day 4 post ICU admission 11. Sodium concentration on day 7 post ICU admission 12. Hypernatremia >150mmol/l free days through day 28. 13. ICU-aquired hypernatremia >155 mmol/l through day 28 14. ICU-aquired hypernatremia >160 mmol/l through day 28 15. ICU-aquired hypernatremia >145 mmol/l through day 28	—

Measure

Time frame

1. ICU mortality 2. Hospital-free days through day 28 3. In-Hospital Mortality 4. Length of Stay in the ICU 5. Length of Stay in the hospital 6. Ventilator free days through day 28 7. Prevalence of new kidney replacement therapy in the first 28 days 8. Duration of new kidney replacement therapy in the first 28 days 9. Peak Creatinine in the first 28 days 10. Sodium concentration on day 4 post ICU admission 11. Sodium concentration on day 7 post ICU admission 12. Hypernatremia >150mmol/l free days through day 28. 13. ICU-aquired hypernatremia >155 mmol/l through day 28 14. ICU-aquired hypernatremia >160 mmol/l through day 28 15. ICU-aquired hypernatremia >145 mmol/l through day 28

—

Countries

Germany

Contacts

Public ContactPhilipp Enghard

Klinik mit Schwerpunkt Nephrologie und internistische Intensivmedizin, Charité Universitätsmedizin Berlin

Philipp.enghard@charite.de+4930450614016

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026